Cantor Fitzgerald Reiterates Overweight on Artiva Biotherapeutics, $40 Price Target
Cantor Fitzgerald maintained its Overweight rating on Artiva Biotherapeutics's stock and set a price target of $40.00, implying a potential upside of 489.1% from the previous closing price.